Compare AMSC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSC | NRIX |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2012 | 2020 |
| Metric | AMSC | NRIX |
|---|---|---|
| Price | $37.71 | $16.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $52.00 | $30.50 |
| AVG Volume (30 Days) | 849.8K | ★ 1.2M |
| Earning Date | 05-20-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 143.24 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | $900,000.00 | ★ $76,987,000.00 |
| Revenue This Year | $34.98 | N/A |
| Revenue Next Year | $21.38 | $40.12 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $17.16 | $8.20 |
| 52 Week High | $70.49 | $22.50 |
| Indicator | AMSC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 54.96 |
| Support Level | $29.09 | $14.61 |
| Resistance Level | $38.10 | $16.47 |
| Average True Range (ATR) | 2.20 | 0.99 |
| MACD | 0.52 | 0.17 |
| Stochastic Oscillator | 85.04 | 66.04 |
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.